{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:40:30Z","timestamp":1793932830117,"version":"4.8.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>X-linked retinitis pigmentosa (XLRP) is a severe cause of early-onset RP in male individuals, characterized by degeneration of photoreceptors, an extinguished electroretinogram, and vision loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the duration of improvements in retinal sensitivity associated with a single, subretinal injection of cotoretigene toliparvovec (BIIB112\/AAV8-RPGR) gene therapy after vitrectomy surgery in the dosed eye over 12 months in part 1 of the Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS) study, compared with untreated fellow eyes and eyes from the untreated subgroup from the Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a post hoc analysis of the XIRIUS and XOLARIS studies. Part 1 of the XIRIUS study was a phase 1, dose-escalation study of 18 male participants 18 years or older enrolled between March 8, 2017, and October 16, 2018, with genetically confirmed <jats:italic>RPGR<\/jats:italic>-variant XLRP with active disease and best-corrected visual acuity better than or equal to light perception (cohort 1), 34 to 73 letters (20\/40 to 20\/200 Snellen equivalent; cohorts 2-3), or greater than or equal to 34 letters (better than or equal to 20\/200 Snellen equivalent; cohorts 4-6). Participants from the noninterventional, multicenter, global, prospective XOLARIS clinical study who met the inclusion and exclusion criteria of part 1 of XIRIUS were included as a comparator group (n\u2009=\u2009103). Safety assessments included all XIRIUS participants; post hoc associations of retinal sensitivity assessments in XIRIUS only included the 12 participants receiving the 4 highest doses of cotoretigene toliparvovec. Data were analyzed on June 30, 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events, changes from baseline in retinal sensitivity (as assessed by macular integrity assessment microperimetry), retinal sensitivity response (achievement of \u22657-dB improvement from baseline at \u22655 of 16 central loci), and low-luminance visual acuity were assessed over 24 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 18 participants (mean [SD] age, 31.9 [9.4] years; male, 100%) were enrolled and completed the XIRIUS study. A subgroup of 103 participants (mean [SD] age, 30.8 [11.4] years; male, 100%) from the XOLARIS study was included. Administration of the 4 highest doses of cotoretigene toliparvovec (n\u2009=\u200912) among the 18 XIRIUS participants was associated with early improvements in retinal sensitivity. One of 103 untreated participants (1%) in the XOLARIS subgroup achieved improved retinal sensitivity at month 12. No DLTs were noted at any dose, and serious adverse events of reduced visual acuity (n\u2009=\u20092) and noninfective retinitis (n\u2009=\u20091) occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results suggest that early and sustained improvements in retinal sensitivity and low-luminance visual acuity in some participants through 12 months support consideration of additional clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: XIRIUS: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03116113\">NCT03116113<\/jats:ext-link>; XOLARIS: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04926129\">NCT04926129<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.6254","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T16:01:57Z","timestamp":1675958517000},"page":"275","source":"Crossref","is-referenced-by-count":73,"title":["Changes in Retinal Sensitivity Associated With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa With <i>RPGR<\/i> Gene Variations"],"prefix":"10.1001","volume":"141","author":[{"given":"Lenore","family":"von Krusenstiern","sequence":"first","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now at BlueRock Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Liu","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now at Kallyope, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Liao","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now at Moderna, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Gow","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now at Beam Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Ong","sequence":"additional","affiliation":[{"name":"Biogen, Cambridge, Massachusetts"},{"name":"Now at Ring Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lotery","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences Research Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom"},{"name":"University Hospital NHS Foundation, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assad","family":"Jalil","sequence":"additional","affiliation":[{"name":"Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron L.","family":"Lam","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[{"name":"Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Eye Hospital, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"XIRIUS Part 1 Study GroupXOLARIS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran H.","family":"Yusuf","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Cehajic-Kapetanovic","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep S.","family":"Josan","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Martinez-Fernandez de la Camera","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwah\u00a0","family":"Rehman","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Wood","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasleen K.","family":"Jolly","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanmin\u00a0","family":"Xue","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Nanda","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Jasani","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moreno\u00a0","family":"Menghini","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.W.","family":"Buckley","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Paola\u00a0","family":"Salvetti","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh\u00a0","family":"Thulasidharan","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel\u00a0","family":"Kurc","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Khandhadia","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Orsine Murta Dias","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeir\u00a0","family":"Baltmr","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Mandal","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios\u00a0","family":"Tsokolas","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Stanga","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsveta","family":"Ivanova","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhannd","family":"EL-Faouri","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif\u00a0","family":"Shaarawy","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Black","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Louise Davis","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninel","family":"Gregori","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.\u00a0","family":"Mendoza-Santiesteban","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Potyra R.","family":"Rosa","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Evans","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Koenekoop","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Fischer","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Holz","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamron","family":"Khan","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Horowitz","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pennesi","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Birch","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gorin","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Stepien","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacque","family":"Duncan","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Stout","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bakall","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeva-Maria","family":"Sankila","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel","family":"Hoyng","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel","family":"Boon","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meunier","sequence":"additional","affiliation":[{"name":"for the XIRIUS Part 1 Study GroupXOLARIS Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi220092r1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","article-title":"Gene therapy for the treatment of X-linked retinitis pigmentosa.","volume":"6","author":"Martinez-Fernandez De La Camara","year":"2018","journal-title":"Expert Opin Orphan Drugs"},{"issue":"9","key":"eoi220092r2","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1167\/iovs.12-10070","article-title":"RPGR-associated retinal degeneration in human X-linked RP and a murine model.","volume":"53","author":"Huang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"eoi220092r3","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1073\/pnas.97.7.3649","article-title":"A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3).","volume":"97","author":"Hong","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"eoi220092r4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-1-40","article-title":"Retinitis pigmentosa.","volume":"1","author":"Hamel","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"eoi220092r5","first-page":"1307","article-title":"Severe retinal degeneration in women with a c.2543del mutation in ORF15 of the RPGR gene.","volume":"20","author":"Kousal","year":"2014","journal-title":"Mol Vis"},{"issue":"5","key":"eoi220092r6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/13816810.2022.2109686","article-title":"Prevalence of RPGR-mutated X-linked retinitis pigmentosa among males.","volume":"43","author":"Vinikoor-Imler","year":"2022","journal-title":"Ophthalmic Genet"},{"key":"eoi220092r7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exer.2015.06.007","article-title":"RPGR: its role in photoreceptor physiology, human disease, and future therapies.","volume":"138","author":"Megaw","year":"2015","journal-title":"Exp Eye Res"},{"issue":"8","key":"eoi220092r8","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.ymthe.2017.05.005","article-title":"Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in 2 mouse models of X-linked retinitis pigmentosa.","volume":"25","author":"Fischer","year":"2017","journal-title":"Mol Ther"},{"issue":"3","key":"eoi220092r9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"eoi220092r10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase 1 clinical trials.","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"issue":"9","key":"eoi220092r11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space.","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi220092r12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol.","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"21","key":"eoi220092r13","doi-asserted-by":"publisher","first-page":"E2925","DOI":"10.1073\/pnas.1523201113","article-title":"Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations.","volume":"113","author":"Sun","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"eoi220092r14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1167\/iovs.03-0787","article-title":"Dominant, gain-of-function mutant produced by truncation of RPGR.","volume":"45","author":"Hong","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"eoi220092r15","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1093\/hmg\/ddv134","article-title":"A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.","volume":"24","author":"Wu","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"1","key":"eoi220092r16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14712598.2020.1680635","article-title":"RPGR gene therapy presents challenges in cloning the coding sequence.","volume":"20","author":"Martinez-Fernandez de la Camara","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"eoi220092r18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/IAE.0b013e3182469064","article-title":"The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.","volume":"32","author":"Zweifel","year":"2012","journal-title":"Retina"},{"issue":"9","key":"eoi220092r19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","article-title":"Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration.","volume":"115","author":"Sunness","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi220092r20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/tvst.10.2.28","article-title":"Low luminance visual acuity and low luminance deficit in choroideremia and RPGR-associated retinitis pigmentosa.","volume":"10","author":"Wood","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"eoi220092r17","unstructured":"US Food and Drug Administration. Human gene therapy for retinal disorders: guidance for industry. Accessed May 16, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-retinal-disorders"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2801300\/jamaophthalmology_von_krusenstiern_2023_oi_220092_1678899613.53127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:01:53Z","timestamp":1678978913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2801300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.6254","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}